前沿生物与葛兰素史克签署授权许可协议

Core Viewpoint - Frontier Biotech (688221) has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small interfering RNA (siRNA) pipeline products, marking a significant collaboration in the biopharmaceutical sector [1] Group 1: Agreement Details - GSK will obtain exclusive rights for the global development, manufacturing, and commercialization of two siRNA products, one of which is in the Investigational New Drug (IND) application stage, while the other is a preclinical candidate [1] - Frontier Biotech will receive an upfront payment of $40 million and a near-term milestone payment of $13 million [1] - The company could earn up to $950 million in additional milestone payments based on successful development, regulatory approval, and commercialization of the two projects [1] Group 2: Financial Implications - Frontier Biotech will also receive tiered royalties on the global net sales of both products, enhancing its revenue potential from this partnership [1]